辅助性瑞博西尼是否已准备好投入常规使用？ - Suppr

Suppr

超能文献

Is adjuvant ribociclib ready for prime time?

作者信息

Natarajan A, Tolaney S M

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston, USA.

出版信息

Ann Oncol. 2024 Dec;35(12):1200-1201. doi: 10.1016/j.annonc.2024.08.2341. Epub 2024 Sep 4.

DOI:10.1016/j.annonc.2024.08.2341

PMID:39241962

Abstract

摘要

相似文献

Is adjuvant ribociclib ready for prime time?

Ann Oncol. 2024 Dec;35(12):1200-1201. doi: 10.1016/j.annonc.2024.08.2341. Epub 2024 Sep 4.

Adaptive neoadjuvant endocrine therapy screens out prime population of ribociclib intensive adjuvant therapy.

Chin J Cancer Res. 2025 Jan 30;37(1):115-117. doi: 10.21147/j.issn.1000-9604.2025.01.08.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2- early breast cancer.

Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. eCollection 2023.

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.

Curr Oncol. 2025 Mar 25;32(4):192. doi: 10.3390/curroncol32040192.

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

NPJ Breast Cancer. 2025 Jan 7;11(1):2. doi: 10.1038/s41523-024-00708-5.

Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.

JCO Glob Oncol. 2024 Jul;10:e2300433. doi: 10.1200/GO.23.00433.

Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.

Clin Breast Cancer. 2025 Feb;25(2):e159-e169.e2. doi: 10.1016/j.clbc.2024.08.022. Epub 2024 Aug 29.

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Ann Oncol. 2025 Feb;36(2):149-157. doi: 10.1016/j.annonc.2024.10.015. Epub 2024 Oct 21.

Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.

NPJ Breast Cancer. 2025 Feb 1;11(1):10. doi: 10.1038/s41523-025-00726-x.

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.

Breast Cancer (Dove Med Press). 2022 Apr 12;14:101-111. doi: 10.2147/BCTT.S341857. eCollection 2022.

引用本文的文献

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.

Curr Oncol. 2025 Mar 25;32(4):192. doi: 10.3390/curroncol32040192.

Adaptive neoadjuvant endocrine therapy screens out prime population of ribociclib intensive adjuvant therapy.

Chin J Cancer Res. 2025 Jan 30;37(1):115-117. doi: 10.21147/j.issn.1000-9604.2025.01.08.

Prognostic implications of risk definitions from the monarchE and NATALEE trials.

J Natl Cancer Inst. 2025 Jun 1;117(6):1198-1208. doi: 10.1093/jnci/djaf031.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验